NCT04982146View on ClinicalTrials.gov

Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2023

Conditions
Pseudomyxoma Peritonei
Interventions
DRUG

Bromelin

0.5mg per mL of total tumor volume calculated, administered percutaneously

DRUG

N-Acetylcysteine

20mg per mL of total tumor volume calculated, administered percutaneously

Trial Locations (1)

14004

Hospital Universitario Reina Sofía, Córdoba

Sponsors
All Listed Sponsors
lead

Maimónides Biomedical Research Institute of Córdoba

OTHER